Paul Maroni
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 39 | 2024 | 999 | 3.960 |
Why?
| Prostatectomy | 8 | 2019 | 103 | 1.540 |
Why?
| Testicular Neoplasms | 7 | 2023 | 102 | 1.150 |
Why?
| Urology | 3 | 2020 | 57 | 0.880 |
Why?
| Embolism | 1 | 2021 | 40 | 0.720 |
Why?
| Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 70 | 0.710 |
Why?
| Urethra | 1 | 2021 | 52 | 0.710 |
Why?
| Androgen Antagonists | 4 | 2024 | 79 | 0.700 |
Why?
| Laser Therapy | 1 | 2021 | 129 | 0.640 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 1005 | 0.490 |
Why?
| Kidney Medulla | 2 | 2005 | 34 | 0.470 |
Why?
| Early Detection of Cancer | 5 | 2023 | 371 | 0.440 |
Why?
| Neoadjuvant Therapy | 2 | 2021 | 379 | 0.390 |
Why?
| Male | 56 | 2024 | 63759 | 0.370 |
Why?
| Urination Disorders | 1 | 2011 | 13 | 0.370 |
Why?
| Prostate-Specific Antigen | 8 | 2020 | 160 | 0.370 |
Why?
| Prostate | 7 | 2023 | 173 | 0.340 |
Why?
| Oxalates | 2 | 2008 | 10 | 0.320 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2014 | 1368 | 0.300 |
Why?
| Neoplasm Grading | 5 | 2021 | 283 | 0.290 |
Why?
| Adenocarcinoma | 3 | 2022 | 893 | 0.280 |
Why?
| Humans | 59 | 2024 | 129847 | 0.270 |
Why?
| Radiotherapy, Adjuvant | 2 | 2018 | 208 | 0.270 |
Why?
| Neoplasm Staging | 7 | 2021 | 1282 | 0.250 |
Why?
| Kidney Tubules, Collecting | 1 | 2005 | 30 | 0.240 |
Why?
| Oxalic Acid | 1 | 2004 | 4 | 0.230 |
Why?
| Brachytherapy | 2 | 2016 | 104 | 0.230 |
Why?
| Clinical Competence | 1 | 2012 | 1020 | 0.230 |
Why?
| Urinary Bladder Neoplasms | 2 | 2021 | 226 | 0.220 |
Why?
| Androgens | 4 | 2024 | 177 | 0.200 |
Why?
| Paraganglioma | 1 | 2022 | 49 | 0.190 |
Why?
| Adrenal Gland Neoplasms | 1 | 2022 | 83 | 0.190 |
Why?
| Cell Hypoxia | 2 | 2015 | 234 | 0.180 |
Why?
| Aged | 21 | 2021 | 22107 | 0.180 |
Why?
| Surveys and Questionnaires | 3 | 2017 | 5437 | 0.180 |
Why?
| Middle Aged | 20 | 2021 | 31177 | 0.170 |
Why?
| Prolactin | 3 | 1997 | 97 | 0.170 |
Why?
| Adaptor Proteins, Vesicular Transport | 2 | 1997 | 44 | 0.170 |
Why?
| Cation Transport Proteins | 1 | 2022 | 131 | 0.170 |
Why?
| Orchiectomy | 3 | 2016 | 67 | 0.170 |
Why?
| Magnetic Resonance Imaging, Interventional | 1 | 2020 | 23 | 0.170 |
Why?
| Risk Assessment | 4 | 2020 | 3269 | 0.170 |
Why?
| Salvage Therapy | 2 | 2018 | 136 | 0.160 |
Why?
| Stromal Cells | 1 | 2019 | 106 | 0.160 |
Why?
| Biflavonoids | 1 | 2019 | 9 | 0.160 |
Why?
| Proanthocyanidins | 1 | 2019 | 10 | 0.160 |
Why?
| Hospitals | 2 | 2023 | 649 | 0.150 |
Why?
| Catechin | 1 | 2019 | 24 | 0.150 |
Why?
| Euterpe | 1 | 2018 | 4 | 0.150 |
Why?
| Anthocyanins | 1 | 2019 | 31 | 0.150 |
Why?
| Grape Seed Extract | 1 | 2019 | 44 | 0.150 |
Why?
| Nomograms | 1 | 2019 | 47 | 0.150 |
Why?
| Neoplasm Recurrence, Local | 2 | 2018 | 957 | 0.150 |
Why?
| Digital Rectal Examination | 1 | 2018 | 10 | 0.150 |
Why?
| Adaptor Proteins, Signal Transducing | 2 | 1997 | 399 | 0.140 |
Why?
| Reagent Kits, Diagnostic | 1 | 2018 | 43 | 0.140 |
Why?
| Urinary Tract Infections | 1 | 2019 | 151 | 0.140 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 187 | 0.140 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 1997 | 131 | 0.140 |
Why?
| Surgical Wound Infection | 2 | 2019 | 283 | 0.140 |
Why?
| Proton Therapy | 1 | 2017 | 12 | 0.140 |
Why?
| Biopsy, Needle | 2 | 2016 | 187 | 0.140 |
Why?
| Seminoma | 1 | 2017 | 18 | 0.130 |
Why?
| Neoplasm Metastasis | 5 | 2019 | 610 | 0.130 |
Why?
| Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.130 |
Why?
| Radiology | 1 | 2019 | 159 | 0.130 |
Why?
| Plant Extracts | 1 | 2018 | 198 | 0.130 |
Why?
| Medical Oncology | 1 | 2019 | 268 | 0.130 |
Why?
| Liver | 4 | 1997 | 1839 | 0.130 |
Why?
| Spectrum Analysis | 1 | 2016 | 89 | 0.130 |
Why?
| Prognosis | 7 | 2019 | 3773 | 0.130 |
Why?
| Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.120 |
Why?
| Radiotherapy, Conformal | 1 | 2015 | 69 | 0.120 |
Why?
| Lymphatic Metastasis | 3 | 2014 | 320 | 0.120 |
Why?
| Risk | 2 | 2015 | 860 | 0.120 |
Why?
| Proto-Oncogene Proteins | 2 | 1997 | 634 | 0.120 |
Why?
| Neoplastic Stem Cells | 1 | 2019 | 378 | 0.120 |
Why?
| HSP70 Heat-Shock Proteins | 2 | 2008 | 69 | 0.120 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2015 | 128 | 0.110 |
Why?
| Genomics | 1 | 2019 | 716 | 0.110 |
Why?
| Biopsy | 4 | 2023 | 1089 | 0.110 |
Why?
| Cause of Death | 1 | 2016 | 395 | 0.110 |
Why?
| Leydig Cell Tumor | 1 | 2014 | 7 | 0.110 |
Why?
| Receptors, Adrenergic, alpha | 1 | 2013 | 31 | 0.110 |
Why?
| Priapism | 1 | 2013 | 11 | 0.110 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2013 | 33 | 0.110 |
Why?
| Optics and Photonics | 1 | 2014 | 43 | 0.110 |
Why?
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.110 |
Why?
| Hypertension | 1 | 2022 | 1242 | 0.110 |
Why?
| Extracellular Vesicles | 1 | 2015 | 129 | 0.100 |
Why?
| Spectrometry, Fluorescence | 1 | 2014 | 164 | 0.100 |
Why?
| Treatment Outcome | 7 | 2018 | 10241 | 0.100 |
Why?
| Proline | 1 | 2013 | 76 | 0.100 |
Why?
| Triglycerides | 1 | 2015 | 528 | 0.100 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2010 | 124 | 0.100 |
Why?
| Neoplasm Invasiveness | 4 | 2016 | 484 | 0.100 |
Why?
| Telephone | 1 | 2013 | 168 | 0.100 |
Why?
| Drug Interactions | 1 | 2013 | 397 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2024 | 2008 | 0.090 |
Why?
| Survival Rate | 4 | 2017 | 1872 | 0.090 |
Why?
| Signal Transduction | 4 | 2004 | 4935 | 0.090 |
Why?
| Cell Line | 3 | 2008 | 2780 | 0.090 |
Why?
| Lymph Nodes | 1 | 2014 | 471 | 0.090 |
Why?
| Urothelium | 1 | 2011 | 37 | 0.090 |
Why?
| Attitude of Health Personnel | 1 | 2019 | 1106 | 0.090 |
Why?
| Prostatic Hyperplasia | 1 | 2011 | 41 | 0.090 |
Why?
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.090 |
Why?
| Aged, 80 and over | 6 | 2020 | 7066 | 0.090 |
Why?
| Oxygen | 1 | 2015 | 916 | 0.090 |
Why?
| Mitogen-Activated Protein Kinase 1 | 4 | 2008 | 184 | 0.090 |
Why?
| Postoperative Complications | 2 | 2019 | 2481 | 0.090 |
Why?
| Epithelial Cells | 2 | 2008 | 1063 | 0.080 |
Why?
| Carcinogenesis | 2 | 2022 | 214 | 0.080 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 2010 | 53 | 0.080 |
Why?
| Survival Analysis | 2 | 2016 | 1271 | 0.080 |
Why?
| Combined Modality Therapy | 2 | 2016 | 1201 | 0.080 |
Why?
| Spinal Fractures | 1 | 2011 | 84 | 0.080 |
Why?
| Glucose | 1 | 2015 | 1003 | 0.080 |
Why?
| Decision Making | 1 | 2017 | 864 | 0.080 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2009 | 277 | 0.080 |
Why?
| Counseling | 1 | 2013 | 386 | 0.080 |
Why?
| Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 151 | 0.080 |
Why?
| Survivors | 1 | 2013 | 464 | 0.080 |
Why?
| Carcinoma | 1 | 2011 | 213 | 0.080 |
Why?
| Lymph Node Excision | 2 | 2014 | 164 | 0.080 |
Why?
| Lymphatic Diseases | 1 | 2009 | 21 | 0.080 |
Why?
| Cystitis | 1 | 2009 | 22 | 0.080 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 35 | 0.080 |
Why?
| Age Factors | 4 | 2017 | 3161 | 0.070 |
Why?
| Logistic Models | 3 | 2019 | 1989 | 0.070 |
Why?
| Patient Selection | 2 | 2018 | 660 | 0.070 |
Why?
| Patient Education as Topic | 1 | 2013 | 743 | 0.070 |
Why?
| Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.070 |
Why?
| Databases, Factual | 3 | 2019 | 1269 | 0.070 |
Why?
| Proportional Hazards Models | 3 | 2016 | 1199 | 0.070 |
Why?
| Cell Line, Tumor | 5 | 2015 | 3185 | 0.070 |
Why?
| Adult | 12 | 2020 | 35634 | 0.070 |
Why?
| Societies, Medical | 1 | 2011 | 759 | 0.070 |
Why?
| Time Factors | 4 | 2014 | 6550 | 0.070 |
Why?
| Image-Guided Biopsy | 2 | 2020 | 37 | 0.070 |
Why?
| Kidney Tubules, Proximal | 1 | 2008 | 125 | 0.070 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2008 | 155 | 0.070 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 274 | 0.070 |
Why?
| Chemotherapy, Adjuvant | 1 | 2008 | 377 | 0.070 |
Why?
| Diagnostic Imaging | 2 | 2022 | 326 | 0.070 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 182 | 0.070 |
Why?
| Radiotherapy Dosage | 2 | 2018 | 251 | 0.070 |
Why?
| Reactive Oxygen Species | 2 | 2009 | 592 | 0.060 |
Why?
| Animals | 11 | 2022 | 35409 | 0.060 |
Why?
| Follow-Up Studies | 4 | 2016 | 4896 | 0.060 |
Why?
| Young Adult | 6 | 2020 | 12467 | 0.060 |
Why?
| Oxidative Stress | 2 | 2010 | 1264 | 0.060 |
Why?
| Ear, Inner | 1 | 2005 | 45 | 0.060 |
Why?
| Isoflavones | 1 | 2005 | 25 | 0.060 |
Why?
| Mice | 4 | 2022 | 16983 | 0.060 |
Why?
| Support Vector Machine | 2 | 2016 | 38 | 0.060 |
Why?
| History, 21st Century | 1 | 2006 | 186 | 0.060 |
Why?
| Body Fluids | 1 | 2005 | 63 | 0.060 |
Why?
| Mitotic Index | 2 | 2015 | 26 | 0.060 |
Why?
| Informed Consent | 1 | 2006 | 165 | 0.060 |
Why?
| Cell Count | 1 | 2005 | 318 | 0.060 |
Why?
| Urinary Incontinence | 1 | 2005 | 62 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2009 | 347 | 0.060 |
Why?
| Disease Progression | 2 | 2018 | 2628 | 0.060 |
Why?
| Growth | 1 | 2004 | 59 | 0.060 |
Why?
| MAP Kinase Signaling System | 2 | 2008 | 314 | 0.060 |
Why?
| Propensity Score | 2 | 2016 | 266 | 0.060 |
Why?
| United States | 5 | 2019 | 13913 | 0.050 |
Why?
| Mass Screening | 2 | 2015 | 1192 | 0.050 |
Why?
| Cell Proliferation | 3 | 2019 | 2378 | 0.050 |
Why?
| Receptors, Nicotinic | 1 | 2005 | 329 | 0.050 |
Why?
| Multivariate Analysis | 2 | 2017 | 1501 | 0.050 |
Why?
| Kaplan-Meier Estimate | 2 | 2016 | 851 | 0.050 |
Why?
| Protein-Tyrosine Kinases | 2 | 1997 | 431 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2013 | 2045 | 0.050 |
Why?
| Urinary Bladder | 1 | 2004 | 176 | 0.050 |
Why?
| Transcriptional Regulator ERG | 1 | 2022 | 19 | 0.050 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 1847 | 0.050 |
Why?
| Rats, Wistar | 3 | 1997 | 443 | 0.050 |
Why?
| Rats | 6 | 2005 | 5487 | 0.050 |
Why?
| Serine Endopeptidases | 1 | 2022 | 120 | 0.050 |
Why?
| Cell Survival | 2 | 2019 | 1086 | 0.050 |
Why?
| Testosterone | 2 | 2015 | 372 | 0.050 |
Why?
| Intestines | 1 | 2004 | 350 | 0.050 |
Why?
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1997 | 12 | 0.040 |
Why?
| Shc Signaling Adaptor Proteins | 2 | 1997 | 12 | 0.040 |
Why?
| Hyperthermia, Induced | 1 | 2001 | 108 | 0.040 |
Why?
| Biomarkers, Tumor | 2 | 2020 | 1161 | 0.040 |
Why?
| Adolescent | 5 | 2022 | 20451 | 0.040 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 284 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2022 | 201 | 0.040 |
Why?
| Fever | 1 | 2001 | 298 | 0.040 |
Why?
| Retrospective Studies | 4 | 2023 | 14553 | 0.040 |
Why?
| Cerebellum | 1 | 2001 | 218 | 0.040 |
Why?
| Inflammation | 1 | 2010 | 2748 | 0.040 |
Why?
| Feeding Behavior | 1 | 2005 | 626 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2022 | 319 | 0.040 |
Why?
| Reperfusion | 2 | 1996 | 38 | 0.040 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2001 | 312 | 0.040 |
Why?
| Jagged-1 Protein | 1 | 2019 | 23 | 0.040 |
Why?
| Geography | 1 | 2019 | 189 | 0.040 |
Why?
| Fruit and Vegetable Juices | 1 | 2018 | 14 | 0.040 |
Why?
| Zinc | 1 | 2022 | 286 | 0.040 |
Why?
| Receptor, Notch1 | 1 | 2019 | 62 | 0.040 |
Why?
| Quality of Life | 2 | 2013 | 2695 | 0.040 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 87 | 0.040 |
Why?
| Stress, Physiological | 1 | 2001 | 412 | 0.040 |
Why?
| Tissue Kallikreins | 1 | 2018 | 2 | 0.040 |
Why?
| Radiometry | 1 | 2018 | 48 | 0.040 |
Why?
| Spheroids, Cellular | 1 | 2019 | 76 | 0.040 |
Why?
| Kallikreins | 1 | 2018 | 29 | 0.040 |
Why?
| Enzyme Activation | 4 | 2008 | 813 | 0.040 |
Why?
| Janus Kinase 2 | 1 | 1997 | 31 | 0.040 |
Why?
| Enzyme Induction | 1 | 1997 | 90 | 0.040 |
Why?
| Carrier Proteins | 1 | 2022 | 741 | 0.040 |
Why?
| Cells, Cultured | 1 | 2005 | 4102 | 0.040 |
Why?
| MAP Kinase Kinase 1 | 1 | 1997 | 75 | 0.030 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 129 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2019 | 931 | 0.030 |
Why?
| National Cancer Institute (U.S.) | 1 | 2017 | 43 | 0.030 |
Why?
| Phosphorylation | 4 | 2008 | 1716 | 0.030 |
Why?
| Health Care Surveys | 1 | 2019 | 558 | 0.030 |
Why?
| Prospective Studies | 2 | 2020 | 7158 | 0.030 |
Why?
| Phenotype | 3 | 2010 | 3062 | 0.030 |
Why?
| Ultrasonography | 1 | 2020 | 713 | 0.030 |
Why?
| Protein Kinase C | 2 | 1994 | 262 | 0.030 |
Why?
| Feminization | 1 | 2015 | 6 | 0.030 |
Why?
| Epoxy Compounds | 1 | 2015 | 33 | 0.030 |
Why?
| Environmental Exposure | 1 | 2019 | 463 | 0.030 |
Why?
| Female | 7 | 2021 | 68829 | 0.030 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 45 | 0.030 |
Why?
| Altitude | 1 | 2019 | 462 | 0.030 |
Why?
| Heterografts | 1 | 2015 | 134 | 0.030 |
Why?
| Proteins | 2 | 1997 | 944 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 647 | 0.030 |
Why?
| Ischemia | 2 | 1996 | 405 | 0.030 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 1995 | 135 | 0.030 |
Why?
| Cell Movement | 1 | 2019 | 950 | 0.030 |
Why?
| Colorado | 2 | 2015 | 4410 | 0.030 |
Why?
| Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
| Positron-Emission Tomography | 1 | 2015 | 282 | 0.030 |
Why?
| Immunohistochemistry | 2 | 2010 | 1690 | 0.030 |
Why?
| Risk Factors | 2 | 2019 | 9801 | 0.030 |
Why?
| Mice, Nude | 1 | 2015 | 680 | 0.030 |
Why?
| Needles | 1 | 2014 | 57 | 0.030 |
Why?
| Radiotherapy | 1 | 2014 | 185 | 0.030 |
Why?
| Aging | 3 | 2010 | 1774 | 0.030 |
Why?
| SEER Program | 1 | 2014 | 202 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2013 | 88 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 1995 | 412 | 0.030 |
Why?
| Estrogens | 1 | 2015 | 348 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1995 | 373 | 0.020 |
Why?
| Child | 3 | 2022 | 20962 | 0.020 |
Why?
| Lipid Metabolism | 1 | 2015 | 503 | 0.020 |
Why?
| Equipment Design | 1 | 2014 | 514 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2015 | 1031 | 0.020 |
Why?
| Reoperation | 1 | 2014 | 542 | 0.020 |
Why?
| Population Surveillance | 1 | 2014 | 439 | 0.020 |
Why?
| Life Style | 1 | 2013 | 462 | 0.020 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2011 | 307 | 0.020 |
Why?
| Atrophy | 1 | 2010 | 170 | 0.020 |
Why?
| Cell Separation | 1 | 2011 | 316 | 0.020 |
Why?
| Anxiety | 1 | 2017 | 976 | 0.020 |
Why?
| Apoptosis | 1 | 2019 | 2489 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2011 | 399 | 0.020 |
Why?
| Cohort Studies | 1 | 2020 | 5444 | 0.020 |
Why?
| Feasibility Studies | 1 | 2013 | 870 | 0.020 |
Why?
| DNA Primers | 1 | 2010 | 508 | 0.020 |
Why?
| Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| Prostatitis | 1 | 2009 | 18 | 0.020 |
Why?
| Metaplasia | 1 | 2009 | 57 | 0.020 |
Why?
| Imaging, Three-Dimensional | 1 | 2012 | 530 | 0.020 |
Why?
| Social Support | 1 | 2013 | 587 | 0.020 |
Why?
| JNK Mitogen-Activated Protein Kinases | 2 | 2001 | 161 | 0.020 |
Why?
| Incidence | 1 | 2015 | 2646 | 0.020 |
Why?
| Tumor Stem Cell Assay | 1 | 2008 | 32 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2013 | 1214 | 0.020 |
Why?
| NADPH Oxidases | 1 | 2009 | 108 | 0.020 |
Why?
| Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2020 | 3397 | 0.020 |
Why?
| Adaptation, Psychological | 1 | 2013 | 618 | 0.020 |
Why?
| Genes, Immediate-Early | 1 | 2008 | 19 | 0.020 |
Why?
| Practice Patterns, Physicians' | 1 | 2017 | 1274 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 954 | 0.020 |
Why?
| Immunoblotting | 2 | 2001 | 306 | 0.020 |
Why?
| Pilot Projects | 1 | 2013 | 1597 | 0.020 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2008 | 52 | 0.020 |
Why?
| Tyrosine | 2 | 2001 | 223 | 0.020 |
Why?
| Receptors, Androgen | 1 | 2009 | 143 | 0.020 |
Why?
| Gonadal Steroid Hormones | 1 | 2009 | 132 | 0.020 |
Why?
| DNA, Mitochondrial | 1 | 2009 | 190 | 0.020 |
Why?
| Blotting, Western | 1 | 2010 | 1204 | 0.020 |
Why?
| RNA, Messenger | 2 | 2008 | 2703 | 0.020 |
Why?
| Glutathione | 1 | 2009 | 349 | 0.020 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 129 | 0.020 |
Why?
| Hypoglycemic Agents | 1 | 2015 | 1221 | 0.020 |
Why?
| Base Sequence | 1 | 2010 | 2142 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2008 | 590 | 0.020 |
Why?
| Phosphotyrosine | 2 | 1996 | 36 | 0.020 |
Why?
| Models, Animal | 1 | 2008 | 376 | 0.020 |
Why?
| Equol | 1 | 2005 | 5 | 0.020 |
Why?
| Chinchilla | 1 | 2005 | 37 | 0.020 |
Why?
| Guinea Pigs | 1 | 2005 | 157 | 0.020 |
Why?
| Swine | 1 | 2008 | 761 | 0.010 |
Why?
| Antioxidants | 1 | 2009 | 558 | 0.010 |
Why?
| Stress, Psychological | 1 | 2013 | 1070 | 0.010 |
Why?
| Bladder Exstrophy | 1 | 2004 | 17 | 0.010 |
Why?
| Acid-Base Equilibrium | 1 | 2004 | 27 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2009 | 1434 | 0.010 |
Why?
| Bicarbonates | 1 | 2004 | 42 | 0.010 |
Why?
| Meat | 1 | 2005 | 93 | 0.010 |
Why?
| Biomarkers | 1 | 2015 | 3971 | 0.010 |
Why?
| Infant, Newborn | 1 | 2015 | 5772 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2511 | 0.010 |
Why?
| Meningomyelocele | 1 | 2004 | 56 | 0.010 |
Why?
| Body Height | 1 | 2004 | 192 | 0.010 |
Why?
| Hypoxia | 1 | 2010 | 1087 | 0.010 |
Why?
| Referral and Consultation | 1 | 2009 | 735 | 0.010 |
Why?
| Infant | 1 | 2015 | 9018 | 0.010 |
Why?
| Receptor, IGF Type 1 | 1 | 2001 | 64 | 0.010 |
Why?
| Child, Preschool | 1 | 2015 | 10522 | 0.010 |
Why?
| Bone Density | 1 | 2004 | 463 | 0.010 |
Why?
| Animals, Newborn | 1 | 2001 | 834 | 0.010 |
Why?
| Neoplasms | 1 | 2013 | 2454 | 0.010 |
Why?
| Gene Expression Regulation | 1 | 2008 | 2545 | 0.010 |
Why?
| ErbB Receptors | 1 | 2001 | 605 | 0.010 |
Why?
| Mutation | 1 | 2009 | 3706 | 0.010 |
Why?
| GRB2 Adaptor Protein | 1 | 1996 | 13 | 0.010 |
Why?
| Proto-Oncogene Proteins c-raf | 1 | 1996 | 45 | 0.010 |
Why?
| Neurons | 1 | 2005 | 1509 | 0.010 |
Why?
| Sialoglycoproteins | 1 | 1996 | 158 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2001 | 2403 | 0.010 |
Why?
| Receptors, Interleukin-1 | 1 | 1996 | 218 | 0.010 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 254 | 0.010 |
Why?
| Lymphocyte Count | 1 | 1995 | 148 | 0.010 |
Why?
| Densitometry | 1 | 1994 | 34 | 0.010 |
Why?
| Phosphotransferases | 1 | 1994 | 24 | 0.010 |
Why?
| Precipitin Tests | 1 | 1994 | 98 | 0.010 |
Why?
| CD4 Lymphocyte Count | 1 | 1995 | 267 | 0.010 |
Why?
| Injections, Intraperitoneal | 1 | 1994 | 112 | 0.010 |
Why?
| Ornithine Decarboxylase | 1 | 1994 | 10 | 0.010 |
Why?
| Genes, myc | 1 | 1994 | 47 | 0.010 |
Why?
| Molecular Weight | 1 | 1994 | 330 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 338 | 0.010 |
Why?
| Cytosol | 1 | 1994 | 219 | 0.010 |
Why?
| Substrate Specificity | 1 | 1994 | 371 | 0.010 |
Why?
| Kinetics | 1 | 1996 | 1645 | 0.010 |
Why?
| Interleukin-1 | 1 | 1996 | 956 | 0.010 |
Why?
| Gene Expression | 1 | 1994 | 1465 | 0.000 |
Why?
| Antibodies, Monoclonal | 1 | 1994 | 1368 | 0.000 |
Why?
| T-Lymphocytes | 1 | 1995 | 1937 | 0.000 |
Why?
|
|
Maroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|